natgillin/translations-raw huggingface dataset:
Anti- GBM-sygdom kan føre til dialysekrævende og/eller transplantationskrævende nyresvigt, hvis det ikke behandles hurtigt, og kan være livstruende, hvis det ikke behandles.
Anti-GBM disease may lead to renal failure requiring dialysis and/or transplantation if not treated rapidly and can be life-threatening if left untreated.
Anti- inflammatoriske midler/Non- steroide antiinflammatorisk e midler
Anti- inflammatory agents/ Nonsteroidal anti- inflammatory agents
Anti- smitstoffer/ Antibiotika
Anti- infectious agents / Antibiotics
Anti- smitstoffer/ Antibiotika
Anti- infectious agents/ Antibiotics’
Anti-angiogenetisk medicin (brugt til behandling af kræft), da en kombination af dette og Zoledronsyre Teva har været forbundet med en øget risiko for osteonekrose i kæberne.
Anti-angiogenic medicines (used to treat cancer), since the combination of these with zoledronic acid has been associated with an increased risk of osteonecrosis of the jaw (ONJ).
Anti-angiogenetisk medicin (brugt til behandling af kræft), da kombination af dette og Zoledronsyre Accord har været forbundet med en øget risiko for osteonekrose i kæberne.
Anti-angiogenic medicines (used to treat cancer), since the combination of these with zoledronic acid has been associated with an increased risk of osteonecrosis of the jaw (ONJ).
Anti-angiogenetisk medicin (brugt til behandling af kræft), da kombination af dette og Zoledronsyre Actavis har været forbundet med en øget risiko for osteonekrose i kæberne.
Anti-angiogenic medicines (used to treat cancer), since the combination of these with zoledronic acid has been associated with an increased risk of osteonecrosis of the jaw (ONJ).
Anti-angiogenetisk medicin (brugt til behandling af kræft), da kombination af dette og Zoledronsyre Hospira har været forbundet med en øget risiko for osteonekrose i kæberne.
Anti-angiogenic medicines (used to treat cancer), since the combination of these with Zoledronic Acid Hospira has been associated with an increased risk of osteonecrosis of the jaw (ONJ).
Anti-angiogenetisk medicin (brugt til behandling af kræft), da kombination af dette og Zoledronsyre Teva har været forbundet med en øget risiko for osteonekrose i kæberne.
Anti-angiogenic medicines (used to treat cancer), since the combination of these with zoledronic acid has been associated with an increased risk of osteonecrosis of the jaw (ONJ).
Anti-angiogenetisk medicin (brugt til behandling af kræft), da kombination af dette og Zometa har været forbundet med en øget risiko for osteonekrose i kæberne.
Anti-angiogenic medicines (used to treat cancer), since the combination of these with Zometa has been associated with an increased risk of osteonecrosis of the jaw (ONJ).
Anti-angiogenetisk medicin (til behandling af kræft), da kombination af dette og zoledronsyre har været forbundet med en øget risiko for osteonekrose i kæberne.
Anti-angiogenic medicines (used to treat cancer), since the combination of these with zoledronic acid has been associated with an increased risk of osteonecrosis of the jaw (ONJ).
Anti-arrythmi-lægemidler og lægemidler mod krampeanfald
Anti-arrhythmics and anti-seizure medicinal products
Anti-arytmika (f.eks. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol).
Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol).
Anti-cholinerge lægemidler (medicin til behandling af en række forskellige lidelser, såsom mavekramper, urinblære spasmer, astma, transportsyge, muskelkramper, Parkinsons sygdom og som en hjælp til bedøvelse) såsom atropin og biperiden.
Anti-cholinergic medicines (medicines used to treat a variety of disorders such as gastrointestinal cramps, urinary bladder spasm, asthma, motion sickness, muscular spasms, Parkinson's disease and as an aid to anaesthesia) such as atropine and biperiden.
Anti-degarelix-antistof
Anti-degarelix antibody
Anti-difteri (0,1 IE/ml) †
Anti-diphtheria (0.1 IU/ml)
Anti-difteri (0,1 IU/ml) †
Anti-diphtheria (0.1 IU/ml)
Anti-difteri ( 0,01 IE/ml)
Anti-diphtheria ( 0.01 IU/ml)
Anti-difteri ( 0,1 IE/ml)
Anti-diphtheria ( 0.1 IU/ml)
anti-dsDNA-niveauet) ved 52 uger (%)
SRI response rate (excluding complement and anti-dsDNA changes) at week 52 (%)
Anti-faktor VIII- antistof positiv2
Anti-Factor VIII antibody positive2
Anti-FHA (Serokonversion ‡‡) (Vaccinerespons§)
Anti FHA (Seroconversion‡‡) (Vaccine response§)
Anti-FHA (Serokonversion ‡‡) (Vaccinerespons§)
Anti-FHA (Seroconversion ‡‡) (Vaccine response§)
Anti-FHA (Serokonversion‡‡) (Vaccinerespons§)
Anti-FHA (Seroconversion‡‡) (Vaccine response§)
Anti-FHA (vaccinerespons)a
Anti-FHA (vaccine response)a
Anti-FIM (vaccinerespons)a
Anti-FIM (vaccine response)a
Anti-HA antistof
Anti-HA antibody
anti-HA ≥1:40
anti-HA ≥1:40
Anti-HA- antistof
anti-HA antibody
Anti-HA-antistofrespons 21 dage efter første dosis er angivet nedenfor:
The anti-HA antibody responses 21 days after a first dose were as follows:
Anti-HBs Ag (≥ 10 mIE/ml)b
Anti-HBs Ag (≥ 10 mIU/mL)b
Anti-HBs- og Anti-HAVs-antistoftitre, som påvises efter et primært vaccinationsforløb med den kombinerede vaccine, ligger indenfor samme område som de, der ses efter vaccination med de monovalente vacciner.
The anti-HBs and anti-HAV antibody titres observed following a primary vaccination course with the combined vaccine are in the range of what is seen following vaccination with the monovalent vaccines.
Anti-HBs-respons på PROCOMVAX hos spædbørn, som ikke tidligere er vaccineret med hepatitis B- vaccine
Anti-HBs Responses to PROCOMVAX in Infants Not Previously Vaccinated with Hepatitis B Vaccine
Anti-HBs-respons på PROCOMVAX hos spædbørn, som tidligere er blevet vaccineret med hepatitis B- vaccine
Anti-HBs Responses to PROCOMVAX in Infants Previously Vaccinated with Hepatitis B Vaccine
Anti-HBsAg
Anti-HBs Ag
Anti-HCV-midler
Anti-HCV agents
Anti-HPV respons ved måned 7 blandt piger og drenge på mellem 9 og 15 år var sammenlignelig med anti-HPV responser hos kvinder på mellem 16 og 26 år i den kombinerede database for immunogenicitetsstudier for Gardasil 9.
Anti-HPV responses at Month 7 among 9- through 15-year-old girls/boys were comparable to anti-HPV responses in 16- through 26-year-old women in the combined database of immunogenicity studies for Gardasil 9.
Anti-HPV-respons i måned 7 hos 9-15-årige drenge antages at være sammenlignelige med anti-HPV- respons hos 16-26-årige mænd, for hvem effekten var blevet bestemt i fase III-studierne.
Anti-HPV responses at Month 7 among 9- to 15-year-old boys were non-inferior to anti-HPV responses in 16- to 26-year-old men for whom efficacy was established in the Phase III studies.
Anti-HPV-responser ved måned 7 blandt 9 til 15 år gamle piger var ikke mindre end anti-HPV- responser i 16 til 26 år gamle kvinder, for hvem effekten var blevet bestemt i fase III-studierne.
Anti-HPV responses at Month 7 among 9- to 15-year-old girls were non-inferior to anti-HPV responses in 16- to 26-year-old women for whom efficacy was established in the phase III studies.
Anti-infektiva
(saquinavir/ritonavir)
ANTI-INFEKTIVA
ANTI-INFECTIVES
Anti-infektiva
Anticonvulsants
Anti-infektiøst middel/antibiotikum
Ant-infectious agent/antibiotic
Anti-inflamma- toriske stoffer/Non- steroide anti- inflammatorisk e stoffer
Anti- inflammatory agents/Nonster oidal anti- inflammatory agents
Anti-ipilimumab-antistoffer havde ikke nogen effekt på ipilimumabs CL.
There was no effect of anti-ipilimumab antibodies on the CL of ipilimumab.
Anti-JCV antistof- negative patienter kan stadig være i risiko for PML af grunde såsom en ny JCV infektion, svingende antistof status eller et falsk negativt testresultat.
Anti-JCV antibody negative patients may still be at risk of PML for reasons such as a new JCV infection, fluctuating antibody status or a false negative test result.
Anti-JCV-antistof-analyser giver information, der kan understøtte risikostratifikation ved TYSABRI- behandling.
Anti-JCV antibody testing provides supportive information for risk stratification of TYSABRI treatment.
Anti-JCV-antistof-analyser, frekvens af analyserne, fortolkning af kvalitative og kvantitative resultater, seroforekomst af JCV-antistoffer og serokonversionsrate over tid
Anti-JCV antibody testing, frequency of testing, interpretation of qualitative and quantitative results, seroprevalence of JCV-antibodies and seroconversion rate over time
Anti-konvulsive midler
Anticonvulsants
Anti-murin IL-1 beta fremkaldte ikke utilsigtede virkninger på føtal eller neonatal vækst ved administration gennem det sene gestationsstadium, fødslen og diegivningen (se pkt.
Anti-murine IL-1 beta did not elicit adverse events on foetal or neonatal growth when administered throughout late gestation, delivery and nursing (see section 4.6).
ANTI-NEOPLASTIKA
ANTI-NEOPLASTICS
Anti-OP-1- antistoffer har evnen til at neutralisere biologisk aktivitet in vitro, i hvert fald af BMP-6.
Anti-OP-1 antibodies have the ability to neutralise the in vitro biological activity of at least BMP-6.
Anti-polio type 1 ( 8 (1/fortynding))
Anti-Polio type 1 ( 8 (1/dilution))
Anti-polio type 2 ( 8 (1/fortynding))
Anti-Polio type 2 ( 8 (1/dilution))
Anti-polio type 3 ( 8 (1/fortynding))
Anti-Polio type 3 ( 8 (1/dilution))
Anti-PRN (vaccinerespons)a
Anti-PRN (vaccine response)a
Anti-PRP (≥ 0,15 µg/ml)
Anti-PRP (≥ 0.15 µg/mL)
Anti-PRP titre på 0,15 µg/ml eller højere og på 1 µg/ml eller højere blev udviklet hos 100 % respektive 96,6 % af småbørnene.
Anti- PRP titres equal to or greater than 0.15 µg/ml and equal to or greater than 1 µg/ml were achieved in 100 % and 96.6 % of toddlers respectively.
Anti-PRP-respons på PROCOMVAX hos spædbørn
Anti-PRP Responses to PROCOMVAX in Infants
Anti-PT (Serokonversion ‡‡) (Vaccinerespons§)
Anti PT (Seroconversion‡‡) (Vaccine response§)
Anti-PT (Serokonversion ‡‡) (Vaccinerespons§)
Anti-PT (Seroconversion ‡‡) (Vaccine response§)
Anti-PT (Serokonversion‡‡) (Vaccinerespons§)
Anti-PT (Seroconversion‡‡) (Vaccine response§)
Anti-PT (vaccinerespons)a
Anti-PT (vaccine response)a
Anti-tetanus (0,1 IE/ml) †
Anti-tetanus (0.1 IU/ml)
Anti-tetanus (0.1 IE/ml) †
Anti-tetanus (0.1 IU/ml)
Anti-tetanus ( 0,01 IE/ml)
Anti-tetanus ( 0.01 IU/ml)
Anti-tetanus ( 0,1 IE/ml)
Anti-tetanus ( 0.1 IU/ml)
Anti-tumor-aktiviteten af topotecan involverer hæmning af topoisomerase-1, et enzym tæt involveret i DNA-replikation, da den eliminerer den torsionale belastning, der opstår foran den bevægelige replikationsgaffel.
The anti-tumour activity of topotecan involves the inhibition of topoisomerase-I, an enzyme intimately involved in DNA replication as it relieves the torsional strain introduced ahead of the moving replication fork.
Anti-tumor-aktiviteten af topotecan involverer hæmning af topoisomerase-I, et enzym tæt involveret i DNA-replikation, da den eliminerer den torsionale belastning, der opstår foran den bevægelige repli- kationsgaffel.
The anti-tumour activity of topotecan involves the inhibition of topoisomerase-I, an enzyme intimately involved in DNA replication as it relieves the torsional strain introduced ahead of the moving replication fork.
Anti-Xa-niveau er stadig detekterbart på disse tidspunkter.
Anti-Xa levels are still detectable at these time points.
Anti-Xa-niveau kan stadig detekteres på disse tidspunkter.
Anti-Xa levels are still detectable at these time points.
Anti-Xa-niveauer kan stadig registreres på disse tidspunkter.
Anti-Xa levels are still detectable at these time points.
Antiallergika (anvendes til behandling af allergier og/eller astma), f.eks.: montelukast, fexofenadin
Anti-allergic medicines (used for the treatment of allergies and/or asthma) for example: montelukast, fexofenadine
Antiarytmika
(mg)
ANTIARYTMIKA
ANTI-ARRYTHMICS
ANTIARYTMIKA
ANTIARRTHYMICS
Antiarytmika
Based on theoretical considerations,
Antiarytmika
Ergotamine
ANTIARYTMIKA
Medicinal product
antiarytmika (amiodaron), som bruges til behandling af arytmier (uregelmæssig hjerterytme)
anti-arrhythmic drugs (amiodarone) used to control arrhythmia (uneven beating of the heart)
antiarytmika (amiodaron), som bruges til behandling af arytmier (uregelmæssig hjerterytme)
anti-arrhythmic medicines (amiodarone) used to control arrhythmia (uneven beating of the heart)
Antiarytmika (f.eks. amiodaron, disopyramid, dofetilid, ibutilid, procainamid, quinidin, hydroquinidin, sotalol).
Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol).
Antiarytmika af klasse I eller III (såsom flecainid, propafenon, quinidin, disopyramid, dofetilid, sotalol, amiodaron) skal seponeres, inden behandling med MULTAQ påbegyndes.
Treatment with Class I or III antiarrhythmics (such as flecainide, propafenone, quinidine, disopyramide, dofetilide, sotalol, amiodarone) must be stopped before starting MULTAQ
Antiarytmika af klasse Ia (f.eks. quinidin), eller klasse III (f.eks. dofetilid og sotalol), bortset fra amiodaron
Class Ia (e.g. quinidine) or Class III (e.g. dofetilide, sotalol) antiarrhythmics other than amiodarone
Antiarytmika Amiodaron, dronedaron
Antiarrhythmics Amiodarone, dronedarone
antiarytmika kan øges ved
antiarrhythmics may be increased
Antiarytmika og andre substanser, der kan forlænge QT
Anti-arrhythmic medicinal products and other substances that may prolong QT
Antiarytmika og antiepilektika
Anti-arrhythmics and anti-seizure medicinal products
Antiarytmika – anvendes til behandling af uregelmæssig hjerterytme
Antiarrhythmics – used to treat an irregular heartbeat
antiarytmika – bruges til at behandle uregelmæssig hjerterytme
anti-arrhythmics – used to treat irregular heart beat;
antiarytmika: amiodaron, quinidin
antiarrhythmics: amiodarone, quinidine
ANTIBAKTERIELLE MIDLER
ANTIBACTERIALS
Antibiotika (anvendes til behandling af bakterieinfektioner), f.eks.: telithromycin, clarithromycin, rifampicin, rifabutin, rifapentin, erythromycin
Antibiotic medicines (used for the treatment of bacterial infections) for example: telithromycin, clarithromycin, rifampicin, rifabutin, rifapentine, erythromycin
Antibiotika (f.eks. clarithromycin, doxycyclin)
Antibiotics (e.g. clarithromycin, doxycycline)
antibiotika (f.eks. erythromycin)
antibiotic medicines (e.g. erythromycin)
antibiotika (f.eks. erythromycin, clarithromycin);
antibiotics (e.g. erythromycin, clarithromycin);
antibiotika (f.eks. rifabutin, rifampicin, clarithromycin);
antibiotics (e.g. rifabutin, rifampicin, clarithromycin);
Antibiotika (fx clarithromycin, doxycyclin)
Antibiotics (e.g. clarithromycin, doxycycline)
antibiotika (herunder rifampin) eller svampedræbende medicin (herunder itraconazol, ketoconazol og voriconazol), der anvendes til behandling af infektioner
antibiotics (including rifampicin) or antifungal medicines (including itraconazole, ketoconazole and voriconazole) used to treat infections
Antibiotika af typen sulfonamider,
Sulfonamide antibiotics.
Antibiotika Fusidinsyre Forhøjede plasmakoncentrationer af fusidinsyre og ritonavir.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid and ritonavir.
Antibiotika Fusidinsyre Forhøjede plasmakoncentrationer af fusidinsyre.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid.
ANTIBIOTIKA MED VIRKNING PÅ MYKOBAKTERIER
11.25 (9.05-13.99)
antibiotika mod infektioner såsom erythromycin
antibiotics for infections such as erythromycin
antibiotika som anvendes til at behandle bakterielle infektioner (telithromycin, rifampicin), lægemidler der bruges til behandling af HIV-infektion og AIDS (ritonavir).
antibiotics used to treat bacterial infections (telithromycin, rifampicin); medicine used to treat HIV infection and AIDS (ritonavir).
Antibiotika stopper væksten af bakterier, som er skyld i infektioner.
Antibiotics stop the growth of bacteria which cause infections.
Antibiotika – makrolider (systemisk administration)
Antifungals (systemic administration)
antibiotika, anvendes til at behandle bakterieinfektioner, herunder tuberkulose, der indeholder:
antibiotics, used to treat bacterial infections including tuberculosis, containing:
Antibiotika, der anvendes til at behandle bakterieinfektioner, herunder tuberkulose, indeholdende:
Antibiotics used to treat bacterial infections including tuberculosis containing:
antibiotika, der anvendes til at behandle bakterieinfektioner, herunder tuberkulose, og indeholder: rifabutin, rifampicin og rifapentin
antibiotics, used to treat bacterial infections including tuberculosis, containing: rifabutin, rifampicin, and rifapentine
Antibiotika, der anvendes til at behandle bakterieinfektioner, som indeholder:
Antibiotics used to treat bacterial infections containing:
antibiotika, f.eks. erythromycin, clarithromycin
antibiotics, e.g. erythromycin, clarithromycin
Antibiotika-præparater (f.eks. rifampicin)
Antimicrobial medicinal products (e.g. rifampicin)
Antibiotika:
Antibacterials:
Antibiotikaresistens er bakteriers evne til at vokse i tilstedeværelse af et antibiotikum, der normalt ville dræbe dem eller begrænse deres vækst.
Antibiotic resistance is the ability of bacteria to grow in the presence of an antibiotic that would normally kill them or limit their growth.
antibiotikummet ciprofloxacin til behandling af infektioner
the antibiotic ciprofloxacin used against infections
Anticancermidler (f.eks. cabazitaxel)
Anticancer agents (e.g. cabazitaxel)
Anticholinesteraser, som fx neostigmin og pyridostigmin (bruges til behandling af muskelsvaghed) eller botulinumtoksin.
Anticholinesterases such as neostigmine and pyridostigmine (used to treat muscle weakness), or botulinum toxin.
ANTICOAGULANTIA
ANTICOAGULANTS
Antidepressiv medicin
Antidepressants
Antidepressiv medicin – tricykliske antidepressiver (f.eks. clomipramin, amoxapin), selektive serotonin-genoptagelseshæmmere (f.eks. citalopram, dapoxetin) og atypiske antidepressiva (f.eks. bupropion)
Antidepressants - tricyclic antidepressants (e.g. clomipramine, amoxapine), selective serotonin reuptake inhibitors (e.g. citalopram, dapoxetine) and atypical antidepressants (e.g. buproprion)
Antidepressiv medicin.
Antidepressants
ANTIDEPRESSIVA
ANTI-DEPRESSANTS
antidepressiva
antidepressants,
Antidepressiva (anvendes til behandling af depression), f.eks.: citalopram, escitalopram, sertralin, bupropion
Antidepressant medicines (used for the treatment of depression) for example: citalopram, escitalopram, sertraline, bupropion
antidepressiva (såkaldt tricykliske antidepressive midler mod depression)
antidepressants (tricyclic antidepressants)
Antidepressiva med serotonerg virkning kan sænke krampetærsklen.
Antidepressants with serotonergic effect can lower the seizure threshold.
Antidepressiva og anxiolytika
Antidepressants and Anxiolytics
Antidepressiva, antipsykotika (inklusive lithium) og benzodiazepiner
Antidepressants, antipsychotics (including lithium) and benzodiazepines
antidepressiva, anvendes til at behandle depression:
antidepressants, used to treat depression:
antidepressivummet.
ANTIFUNGALS
Antidiabetika (medicin, der anvendes til behandling af sukkersyge, såsom metformin depottabletter, glimepirid, glipzid, pioglitazon, repaglinid eller glibenclamid).
Antidiabetic medications (medicines used to treat diabetes, such as metformin extended-release (ER) tablets, glimepiride, glipizide, pioglitazone, repaglinide or glyburide).
Antidiabetika (orale stoffer og insuliner)
Antidiabetic medicinal products (oral agents and insulins)
Antidiabetika, monoaminoxidasehæmmere (MAO-hæmmere), betablokkere, ACE-hæmmere, salicylater, anabolske steroider og sulfonamider.
Anti-diabetic medicinal products, monoamine oxidase inhibitors (MAOI), beta-blockers, angiotensin converting enzyme (ACE) inhibitors, salicylates, anabolic steroids and sulphonamides.
Antidifteri (≥ 0,01 IE/ml)
Anti-diphtheria (≥ 0.01 IU/mL)
Antidifteri (≥ 0,1 IE/ml)
Anti-diphtheria (≥ 0.1 IU/mL)
ANTIDIURETISK HORMON
ANTI-DIURETIC HORMONE
antiemetika, der anvendes til behandling af kvalme og opkastning (f.eks. metoclopramid)
anti-emetics, used to treat nausea and vomiting (e.g. metoclopramide)
antiemetika, der anvendes til behandling af kvalme og opkastning (f.eks. metoclopramid)
antiemetics, used to treat nausea and vomiting (e.g. metoclopramide)
Antiemetisk aktivitet blev vurderet fra den første administration indtil 24 timer efter starten på den sidste dags administration af kemoterapi-programmet med ME eller HE.
Anti-emetic activity was assessed from the first administration until 24 hours after the start of the last day’s administration of the ME or HE chemotherapy regimen.
Antiemetisk forebyggelse anbefales før den initiale dosis af kombinationsfasen, og det anbefales kraftigt under monoterapifasen.
Anti-emetic prophylaxis is recommended prior to the initial dose of concomitant phase and it is strongly recommended during the monotherapy phase.
Antiepileptika
Adverse reaction
ANTIEPILEPTIKA
ANTICOAGULANTS
ANTIEPILEPTIKA
ANTICONVULSANTS
ANTIEPILEPTIKA
Medicinal products by therapeutic area
Antiepileptika (f.eks. carbamazepin, clonazepam, phenytoin, primidon, valproinsyre)
Antiepileptics (e.g. carbamazepine, clonazepam, phenytoin, primidone, valproic acid)
Antiepileptika (fx carbamazepin, phenobarbital, phenytoin)
Antiepileptic agents (e.g. carbamazepine, phenobarbital, phenytoin)
Antiepileptika (fx carbamazepin, phenytoin, primidon, valproat)
Antiepileptic (e.g. carbamazepine, phenytoin, primidone, valproic acid)
Antiepileptika (medicin såsom phenytoin, der anvendes til behandling af epilepsi).
Anti-epileptic medicines (medicines, such as phenytoin, used to treat epilepsy).
antiepileptika (til behandling af epilepsi), f.eks. phenytoin
antiepileptics, (for treating epilepsy) e.g. phenytoin
Antiepileptika.
antiepileptics
antiepileptika.
ANTIHISTAMINE AGENTS
Antiepileptikum administreret samtidig
AED coadministered
Antiepileptikum-overfølsomhedssyndrom forekom i tæt tidsmæssig forbindelse med indledningen af rufinamidbehandling og i den pædiatriske population.
The antiepileptic drug hypersensitivity syndrome occurred in close temporal association to the initiation of rufinamide therapy and in the paediatric population.
Antiepileptikums virkning på plasmakoncentrationen af brivaracetam
Influence of AED on brivaracetam plasma concentration
Antiepileptiske lægemidler kan medvirke til folinsyremangel, som kan være en medvirkende årsag til fosterskader.
Anti-epileptic medicinal products may contribute to folic acid deficiency, a possible contributory cause of foetal abnormality.
antiepileptiske lægemidler, der indeholder:
antiepileptic medicines containing:
Antifungale lægemidler
Antifungals
Antifungale lægemidler:
Anti-fungals:
Antigen findes på  95 % af alle B-celle non-Hodgkin-lymfomer.
The antigen is expressed on 95 % of all B cell non-Hodgkin’s lymphomas.
Antigen suspension til Adjupanrix
Antigen suspension for Adjupanrix
Antigen suspension: Casein hydrolysat Aluminiumhydroxid
Antigen suspension: Casein hydrolysate Aluminium hydroxide
Antigen til HUMENZA injektionsvæske, suspension Pandemisk influenzavaccine (H1N1)
Antigen for HUMENZA suspension for injection Pandemic influenza vaccine (H1N1)
Antigen, suspension til Arepanrix Pandemisk influenzavaccine
Antigen suspension for Arepanrix Pandemic influenza vaccine
Antigen, suspension til Prepandrix Prepandemisk influenzavaccine
Antigen suspension for Prepandrix Prepandemic influenza vaccine
Antigen, suspension til Pumarix Pandemisk influenzavaccine
Antigen suspension for Pumarix Pandemic influenza vaccine
Antigen: Hætteglas (glas)
Antigen: vial (glass)
Antigenerne er adjuveret til 150 mg dl-- tocopherolacetat pr. dosis.
The antigens are adjuvanted with 150 mg dl--tocopherol acetate per dose.
Antigenerne er inkorporerede i en adjuvans baseret på dl--tocopherol.
The immunogens are incorporated in an adjuvant based on dl-α-tocopherol.
Antigenet er en farveløs klar til uigennemskinnelig suspension.
The antigen is a colourless limpid to opalescent suspension.
Antigenet må ikke opbevares længere end 12 måneder ved 2 – 80C i afventen af yderligere data til støtte for en længere opbevaringsperiode.
The antigen should be stored for no longer than 12 months at 2-8ºC pending the provision of data supporting a longer period of storage.
Antigenet udtrykkes på > 95 % af alle B-celle non- Hodgkin-lymfomer.
The antigen is expressed on 95 % of all B cell non-Hodgkin’s lymphomas.